Autopsy report · NCT01005875
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
Cause of deathSlow enrollment
“Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.”
Life of this trial
- Ran for about 3 years 7 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Conditions
- Hepatocellular Carcinoma; Liver Cancer
- Interventions
- Sorafenib; Stereotactic Body Radiotherapy (SBRT)
- Participants
- 5
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
“Bayer is no longer funding due to lack of accrual” - AndraTec PMCF Study : Investigating the AndraTec Guidewires,PTA Balloons and Stents in Iliac Disease.
“Sponsor did not pusue with the study” - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
“sponsor stopped the study because of lack of elligible participants” - Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
“The lack of adequate funding has made it impossible to continue with the clinical study As this study was not initiated, no subject was included and no data was collected,thus no result can be obtained SPONSOR\_DECISION End of trial date:15 Oct 2025” - Duet TRS Used in Pulmonary Resections
“Sponsor is no longer pursuing this study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.